Clinical significance of anti-PEPCK antibody in patients with autoimmune hepatitis

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590987
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Fukushima Medical University
• Principal Investigator: OHIRA Hiromasa 福島県立医科大学, 医学部, 教授 (90274951)
• Co-Investigator(Kenkyū-buntansha): ABE Kazumichi 福島県立医科大学, 消化器・リウマチ膠原病内科, 教授 (30468128) ; WATANABE Hiroshi 福島県立医科大学, 消化器・リウマチ膠原病内科, 教授 (40336467) ; TAKAHASHI Atsushi 福島県立医科大学, 消化器・リウマチ膠原病内科, 助教 (40404868)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 自己免疫性肝炎 / PEPCK抗体 / ＣｐＧＤＮＡ

Outline of Final Research Achievements

Identifying disease-specific autoantibodies that can be used diagnostically or are involved in the pathogenesis of AIH is important. We extracted non-nuclear component protein from normal human liver cells from which PEPCK was identified as an antigenic protein that specifically reacted with the sera from AIH patients, and we evaluated the clinical significance of anti-PEPCK antibody. The sensitivity, specificity and accuracy of anti-PEPCK antibody in diagnosing AIH were 50.0%, 91.5% and 83.1%, respectively. None of the AIH patients positive for anti-PEPCK antibody showed characteristic clinical features. Although further investigations into the clinical usefulness are necessary, anti-PEPCK may have potential as a diagnostic marker for AIH.

Free Research Field

医歯薬学